

Common and differential genetically pathways between ulcerative colitis and colon adenocarcinoma

Somayeh Akbari¹, Mostafa Hosseini¹, Majid Rezaei-Tavirani¹, Mostafa Rezaei-Tavirani², Seyed Hamid Salehi¹, Mahdi Alemrajabi¹, Padina Vaseghi-Maghvan², Somayeh Jahani-Sherafat³

¹Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

²Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: In the present study, genes of Ulcerative Colitis and Colon Adenocarcinoma (COAC) were extracted by string App in Cytoscape software version 3.5.1. Then protein- protein interaction (PPI) networks analyzed.

Background: One of the most common chronic digestive problems is ulcerative colitis (UC) especially in developing countries. Prevalence of the disease is reported about 7.6 to 245 cases per 100,000 per year. UC can lead to colon cancer that is the third malignancy related death in the world. So awareness of the future of the patient with UC and the possibility of colon cancer is a very helpful approach.

Methods: The analysis was based on centralities values. The goal is determining common gene pathways and differential gene pathways of the two diseases.

Results: Results showed there are 11 and 29 central genes related to COAC and UC respectively. At least five common key genes between the two diseases were introduced. The number of 26 terms related to the common key genes were determined and clustered in seven clusters.

Conclusion: ALB, AKT1, TP53, SRC and MYC are the common genes that play crucial roles in the related biological processes of UC and COAC. Besides introducing the common genes the differentiate genes related to the two diseases were proposed.

Keywords: Ulcerative colitis, Colon adenocarcinoma, PPI network, Cytoscape, Gene ontology

(Please cite as: Akbari S, Hosseini M, Rezaei-Tavirani M, Rezaei-Tavirani M, Salehi SH, Alemrajabi M, et al. Common and differential genetically pathways between ulcerative colitis and colon adenocarcinoma. *Gastroenterol Hepatol Bed Bench* 2017;10(3): (Suppl. 1):S93-S101).

Introduction

Colorectal cancer is known as the fourth commonest cancer in the world (1). It is a big problem in industrial countries however, its rate in developing countries is increased (2). Numbers of 49700 related death to colon cancer and 93090 new cases are reported in United States at 2015 (3). Survival of patients related to early diagnosis and since there is no proper and effective method, the mortality rate of colon cancer is high. Studies show people's lifestyle, such as nutrition and

physical activity, are effective (4). In addition to, chronic digestive problems provide conditions for the onset of gastrointestinal cancers (5). Ulcerative Colitis (UC) and Crohn's disease are the most common gastrointestinal inflammations. Many researches showed the connection between the two diseases (6). Investigations revealed that UC after 8-10 years increases significantly the risk of colorectal cancers (7). UC can affect rectum and colon, especially sigmoid colon and rectum are damaged parts in this disease. UC is common at any age and its main reason is unknown but aberrant activity of immune system, genetically factors, excessive and improper activity of colon bacteria or presence of some viruses and unpopular

Received: 13 July 2017 Accepted: 29 September 2017

Reprint or Correspondence: Mostafa Rezaei-Tavirani, PhD. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

E-mail: tavirany@yahoo.com

bacteria in gastrointestinal system were introduced as main risk factors of the disease (8). Diagnostic methods for UC are colonoscopy, blood test for finding out infection and inflammation factors and stool test for finding out blood cells in stool. Removing a part of colon is one of the complications of the disease that suggested to those who have UC for more than 8 years (9). Therefore, identifying the common and different genetic pathways of these two diseases can help to improve the lives of patients with UC. This way, can estimate the risk of colon cancer in people with UC. There are many experiments aimed at discovering the genetic similarities of these two diseases. So some useful protein and genetically data bases have been prepared valuable and extensive information about these two diseases (10, 11). Bioinformatic methods and protein-protein interaction network analysis can introduce common genetically pathways and differential biomarkers for UC and COAC (12, 13).

In this study, all the related genes to UC and COAC were extracted and PPI networks were analyzed that led to introduce differential biomarkers and common genetically pathways between the two diseases.

Methods

The related genes to UC and colon adenocarcinoma were from STRING App. of Cytoscape software version 3.5.1. The related PPI networks of the two diseases were constructed by Cytoscape software separately. The common genes between the two diseases were determined and in addition to the other related genes were included in a PPI network. The networks were analyzed and the central node (hub, bottleneck and hub-bottleneck nodes) were determined. Mean+2SD used as cut off value, to determine the hub-nodes (14). Five percent of top nodes based on betweenness value were selected as bottleneck nodes (15). The common nodes between hub-genes and bottleneck genes were identified as hub-bottleneck nodes (16). Since GO can provide useful information about roles of the genes (17), GO analysis of crucial genes was performed by ClueGO application in cytoscape software. Finally, the determined biological processes were clustered. Statistical significance were $P\text{-value} \leq 0.01$.

Results

The numbers of 843 and 376 related genes to UC and colon adenocarcinoma were extracted from string App. of Cytoscape software. The related networks were constructed and analyzed (Figures 1-2).




Figure 1. PPI network of UC including 843 genes is presented. The nodes are layout based on degree value (the bigger size is corresponded to more amount of degree value).




Figure 2. PPI network of colon adenocarcinoma including 376 genes is presented. The nodes are layout based on degree value (the bigger size is corresponded to more amount of degree value).

Table 1. Hub-bottleneck nodes related to the common genes PPI network are presented.

R	Genes	Description
1	TP53	Cellular tumor antigen p53
2	MYC	Myc proto-oncogene protein
3	CTNNB1	Catenin beta-1
4	SRC	Proto-oncogene tyrosine-protein kinase
5	SMAD2	Src
6	AKT1	Mothers against decapentaplegic
7	HSPA4	homolog 2
8	SMAD4	RAC-alpha serine/threonine-protein
9	FOS	kinase
10	CASS1	Heat shock 70 kDa protein 4
11	ALB	Mothers against decapentaplegic
12	TNFRSF1A	homolog 4
13	HRAS	Proto-oncogene c-Fos
14	PPARG	Cas scaffolding protein family member
15	CDKN2A	1
16	LGALS3	Serum albumin
17	CCND1	Tumor necrosis factor receptor
18	CDH1	superfamily member 1A
19	MSH2	GTPase HRas
20	KRAS	Peroxisome proliferator-activated
21	VDR	receptor gamma
22	BCL2L1	Cyclin-dependent kinase inhibitor 2A
23	MSH6	Galectin-3
24	EGF	G1/S-specific cyclin-D1
25	SMAD7	Cadherin-1
26	CD44	DNA mismatch repair protein Msh2
27	VEGFA	GTPase KRas
28	CDKN2A	Vitamin D3 receptor
29	CAT	Bcl-2-like protein 1
		DNA mismatch repair protein Msh6
		Pro-epidermal growth factor
		Mothers against decapentaplegic
		homolog 7
		CD44 antigen
		Vascular endothelial growth factor A
		Cyclin-dependent kinase inhibitor 2A
		Catalase

As it is shown in figure 3, the network included 4390 nodes which are organized in the two main connected components. As it is depicted in figure 3, component-1 is a small sub network compared to component-2. Therefore, amounts of degree value in component-1 are smaller than the similar values in component-2. When the nodes of the two components analyzed together, the mean value of degree was smaller than the mean value of degree in the case of component-1. This point leads to lower cut off for degree value in the analysis of the nodes of the two components together relative to component-2. In the other hand, the top nodes of component-2 may be vanished. Due to avoiding of possible error the hub and bottleneck nodes for the common genes network were determined in the case of the two situations.

Table 2. Hub-bottleneck nodes related to the two main connected components of common genes PPI network are presented.

R	Hub-bottleneck genes of main connected component-1	Hub-bottleneck genes of main connected component-2
1	TP53	TP53
2	MYC	SNW1
3	CTNNB1	CTNNB1
4	SRC	CASS1
5	SMAD2	
6	AKT1	
7	HSPA4	
8	SMAD4	
9	FOS	
10	ALB	
11	TNFRSF1A	
12	HRAS	
13	PPARG	
14	CDKN2A	
15	LGALS3	
16	CDH1	
17	CCND1	
18	MSH2	

Table 3. Hub-bottleneck nodes related to the COAC PPI network are presented.

R	Gene	Description
1	ALB	Serum albumin
2	TP53	Cellular tumor antigen p53
3	PRDM10	PR domain zinc finger protein 10
4	AKT1	RAC-alpha serine/threonine-protein
5	CTNNB1	kinase
6	EGFR	Catenin beta-1
7	MYC	epidermal growth factor receptor
8	HRAS	Myc proto-oncogene protein
9	SRC	GTPase HRas
10	MAPK3	Proto-oncogene tyrosine-protein kinase
11	EGF	Src
		Mitogen-activated protein kinase 3
		epidermal growth factor

The determined hub-bottleneck nodes of the common genes network, the main connected components of the common genes network and the separated networks of the two diseases are presented in the tables 1-4 respectively. Based on early description and comparing tables 1 and 2, the hub-bottleneck nodes rows 20-29 in table 1 were excluded and SNW1 was added to the content of table 1. The final hub-bottleneck genes of common genes PPI network are shown in the table 5. Hub-bottleneck nodes of UC and COAC networks and the common hub-bottleneck genes between the two diseases are shown in table 6. For more details, see table 6. As it is shown in table 6 five genes including ALB, AKT1, TP53, SRC and MYC were the key genes in the common genes between UC and COAC.


Table 4. Hub-bottleneck nodes related to the UC PPI network are presented.

R	Gene	Description
1	ALB	Serum albumin
2	IL6	Interleukin-6
3	AKT1	RAC-alpha serine/threonine-protein kinase
4	TP53	Cellular tumor antigen p53
5	TNF	Tumor necrosis factor
6	SRC	Proto-oncogene tyrosine-protein kinase Src
7	IL8	Interleukin-8
8	VEGFA	Vascular endothelial growth factor A
9	EGF	epidermal growth factor
10	MAPK3	Mitogen-activated protein kinase 3
11	IL10	Interleukin-10
12	MYC	Myc proto-oncogene protein
13	IL1B	Interleukin-1 beta
14	IL4	Interleukin-4
15	TLR4	Toll-like receptor 4
16	IL2	Interleukin-2
17	FOS	Proto-oncogene c-Fos
18	JUN	Transcription factor AP-1
19	IL13	Interleukin-13
20	TGFB1	Transforming growth factor beta-1
21	CSF2	Granulocyte-macrophage colony-stimulating factor
22	ICAM1	Intercellular adhesion molecule 1
23	MAPK8	Intercellular adhesion molecule 1
24	STAT3	Mitogen-activated protein kinase 8
25	IFNG	Signal transducer and activator of transcription 3 Interferon gamma

Table 5. Hub-bottleneck nodes related to the common genes PPI network are presented. Content of this table is provided by comparing tables 1 and 2.

R	Genes	Description
1	TP53	Cellular tumor antigen p53
2	MYC	Myc proto-oncogene protein
3	CTNNB1	Catenin beta-1
4	SRC	Proto-oncogene tyrosine-protein kinase
5	SMAD2	Src
6	AKT1	Mothers against decapentaplegic homolog 2
7	HSPA4	homolog 2
8	SMAD4	RAC-alpha serine/threonine-protein kinase
9	FOS	kinase
10	CASS1	Heat shock 70 kDa protein 4
11	ALB	Mothers against decapentaplegic homolog 4
12	TNFRSF1A	homolog 4
13	HRAS	Proto-oncogene c-Fos
14	PPARG	Cas scaffolding protein family member 1
15	CDKN2A	1
16	LGALS3	Serum albumin
17	CCND1	Tumor necrosis factor receptor superfamily member 1A
18	CDH1	superfamily member 1A
19	MSH2	GTPase HRas
20	SNW1	Peroxisome proliferator-activated receptor gamma, Cyclin-dependent kinase inhibitor 2A, Galectin-3 G1/S-specific cyclin-D1, Cadherin-1 DNA mismatch repair protein Msh2, SNW domain containing 1

Gene ontology analysis of these key genes was performed by ClueGO application of Cytoscape (details were illustrated in figures4-6).

**Figure 5.** The related biological processes of common genes between UC and COAD. Inclusion criteria were at least two genes attribution in term and 4% gene/term. P-value for all terms were less than 0.01.

Discussion

In many cases there are closed similarities between two or more diseases which may lead to misdiagnosis and ineffective treatment of patients (18). Precise diagnosis for such diseases implies complex and in the most condition aggressive tolls and methods. Colonoscopy and pathology evidences are the two well-known diagnostic tools for UC and COAC (19, 20). These approaches are valuable methods in the advanced stage of diseases but a noninvasive, differentially and effective tool especially for early stage detection of diseases always is required. Biomarkers are the specific and sensitive agents that find in the various parts of body and can be used as accurate diagnostic factors




Figure 6. The related biological processes of common genes between UC and COAD are clustered in seven groups. P-value for all terms were less than 0.01.

specially when are accessible in the serum (21). In the recent years suggestion of biomarker panels is attracted more attention in medicine (22, 23). Relationship between large numbers of genes and UC and COAC makes it possible that the two diseases be analyzed via PPI network approach. Construction of two scale free networks (12) provides the numbers of crucial genes which may be critical in diagnosis, differentiation and even treatment of the two diseases.

Network analysis led to introduce 11 and 25 related central genes to COAC and UC respectively. Since the UC network is bigger than COAC network, it is logical that numbers of UC network key genes be more than the key genes of the other network. As it is depicted in table 3 all of the presented genes are well-known oncogenes which are related to the gastrointestinal cancers. In the other hand, the tabulated genes in table 4 include numbers of oncogenes and inflammatory proteins such as IIs. Since the introduced genes for the two diseases are corresponded to the previous studies, it seems that network approach is the right method for gene screening among large numbers of genes. When the content of tables 3 and 4 which correspond to the key genes of the two diseases were compared seven common critical nodes determined. ALB, TP53, AKT1, MYC, SRC, MAPK3 and EGF are the crucial genes in

UC and COAC. In the other hand, network analysis of a constructed network of the 65 common genes (see table 5) led to introduce 20 critical common nodes between the two diseases. ALB, TP53, AKT1, MYC and SRC are five crucial common genes which were determined in the two analytic methods. ALB as an important carrier plays central roles in transferring of various types of ligands in body. Transferring broad spectra of drugs, metabolites and hormones is an essential role of albumin (24, 25). Expression change of ALB in large number of diseases is reported (26, 27). Since albumin is a house keeping gene (28), it is not a specific biomarker for UC or COAC. Expression change of TP53, AKT1, MYC, and SRC in numerous diseases especially cancers is confirmed (29-32). Relationship between TP53 and various kinds of cancers (almost all cancer diseases) is studied and discussed in the precise details (33, 34). However, we focused on common genes related to many cases of cancers but it is possible that the expression patterns as like amounts of expression and down or up regulation of these genes separately or in a combined panel be specific in relationship with a certain cancer. Since about 50% of related key genes of COAC network are presented in the UC it is corresponded to the closed correlation between the two diseases. It seems these

introduced genes are a potent core to change UC to COAC. In the other hand, this closed similarity between two diseases may imply revision in treatment of UC. Probably therapeutic protocol of UC may resemble as COAC at least partially. Treatment of UC mainly is depended to 5-aminosalicylates, corticosteroids, and immunosuppressants, such as purine antimetabolites and cyclosporine (35). However, it is reported that 5-aminosalicylates may be effective in colorectal cancers prevention (36). The Basis of UC treatment is established on corticosteroids in combination with cyclosporine (37).

As it is shown in table 6 seven types of interleukins are correlated to UC. These numbers of ILs are about 40% of the key genes that are presented in the UC network and are not included in the specific panel of COAC. Since UC is essentially related to the inflammatory system, this finding refers to power of PPI network analysis to discover new aspects of diseases.

GO analysis led to introduce 26 related terms to the five crucial common genes, which were clustered in seven groups. Since at least two key genes are involved in each term therefore, 40% central genes are presented in all terms. Positive regulation of DNA biosynthetic process is the smallest group including one term which is related to NYC and SRC genes. It is reported that SRC signaling cascade induces MYC expression and DNA synthesis (38). Regulation of release of cytochrome C from mitochondria is the largest cluster which is correlated to TP53 and AKT1 genes. Regulation of release of cytochrome C from mitochondria is a part of regulation of BCL2 of apoptosis (39). Based on figure 4; AKT1, TP53, SRC, MYC and EGF are involved in four, three, three, three and two clusters respectively. AKT1 is related to 19 terms among 26 terms. This wide participation (it is involved in 73% of total terms) indicates the important role of AKT1 in both diseases. In addition to the role of AK1 in apoptosis and human cancers; its participation in other diseases and disorders such as schizophrenia is reported and discussed in details (40, 41).

It can be concluded that there is a main similarity between UC and COAC which implies revision of therapeutic aspects of UC. It may be application of mild anticancer drugs for treatment of UC added to corticosteroids. The differential elements between the

two studied diseases may be useful in diagnostic features of UC and COAC.

Acknowledgment

This project is supported by Shahid Beheshti University of Medical Sciences. The paper is resulted from MD thesis of Dr Somayeh Akbari.

Conflict of interests

The authors declare that they have no conflict of interest.

References

1. Taghipour N, Aghdai HA, Haghghi A, Mossafa N, Tabaei SJ, Rostami-Nejad M. Potential treatment of inflammatory bowel disease: a review of helminths therapy. *Gastroenterol Hepatol Bed Bench* 2014;7:9-16.
2. Taghipour N, Molaei M, Mosaffa N, Rostami-Nejad M, Asadzadeh Aghdai H, Anissian A, et al. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. *Gastroenterol Hepatol Bed Bench* 2016;9:45-52.
3. Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R, et al. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. *Int J Colorectal Dis* 2007;22:999-1003.
4. Wang B, Dong D, Li E, Wang F, Yang J, Yang J, et al. The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012. *BMC Cancer* 2017;17:783.
5. Ranjzad F, Mahban A, Shemirani AI, Mahmoudi T, Vahedi M, Nikzamir A, et al. Influence of gene variants related to calcium homeostasis on biochemical parameters of women with polycystic ovary syndrome. *J Assist Reprod Genet* 2011;28:225-32.
6. Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, et al. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. *Gastroenterology* 2009;136:523-9.
7. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000;14:145-54.
8. Colitis-Pathophysiology U. Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options. *Altern Med Rev* 2003;8:247-83.
9. Norouzinia M, Asadzadeh H, Shalmani HM, Al Dulaimi D, Zali MR. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. *Asian Pac J Cancer Prev* 2012;13:5677-79.

S100 Common and differential genetically pathways between ulcerative colitis and colon adenocarcinoma

10. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet* 2010;42:332-7.
11. Rostami-Nejad M, Romanos J, Rostami K, Ganji A, Ehsani-Ardakani MJ, Bakhshipour AR, Zojaji H, et al. Allele and haplotype frequencies for HLA-DQ in Iranian celiac disease patients. *World J Gastroenterol* 2014;20:6302-308.
12. Maghvan PV, Rezaei-Tavirani M, Zali H, Nikzamir A, Rostami-Nejad M, Khodadoostan M, et al. Network analysis of common genes related to esophageal, gastric, and colon cancers. *Gastroenterol Hepatol Bed Bench* 2017;10:295-302.
13. Khayer N, Zamanian-Azodi M, Mansouri V, Ghassemi-Broumand M, Rezaei-Tavirani M, Heidari MH, et al. Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. *Gastroenterol Hepatol Bed Bench* 2017;10:118-24.
14. Safari-Alighiarloo N, Taghizadeh M, Tabatabaei SM, Shahsavari S, Namaki S, Khodakarim S, et al. Identification of new key genes for type 1 diabetes through construction and analysis of protein-protein interaction networks based on blood and pancreatic islet transcriptomes. *J Diabetes* 2017;9:764-77.
15. Safari-Alighiarloo N, Rezaei-Tavirani M, Taghizadeh M, Tabatabaei SM, Namaki S. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. *Peer J* 2016;4:2775.
16. Karbalaee R, Piran M, Rezaei-Tavirani M, Asadzadeh-Aghdaei H, Heidari MH. A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. *Gastroenterol Hepatol Bed Bench* 2017;10:194-201.
17. Rezaei-Tavirani M, Okhovatian F, Azodi MZ, Tavirani MR. Duchenne muscular dystrophy (DMD) protein-protein interaction mapping. *Iran J Child Neurol* 2017;11:7-14.
18. Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. *Gastroenterol Hepatol Bed Bench* 2015;8:215-24.
19. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. *Gastroenterology* 2003;124:544-60.
20. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. *Gastroenterology* 1993;105:418-24.
21. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW, et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. *Biosens Bioelectron* 2009;24:3622-9.
22. Lawicki S, Będkowska GE, Gacuta-Szumarska E, Szmítkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. *J Ovarian Res* 2013;6:45.
23. Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, Rad SR, Dalilan S. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. *Gastroenterol Hepatol Bed Bench* 2015;8:6-18.
24. Rezaei-Tavirani M, Moghaddamnia SH, Ranjbar B, Amani M, Marashi SA. Conformational study of human serum albumin in pre-denaturation temperatures by differential scanning calorimetry, circular dichroism and UV spectroscopy. *BMB Reports* 2006;39:530-6.
25. Rezaei-Tavirani M, Tadayon R, Mortazavi SA, Medhet A, Namaki S, Kalantari S, et al. Fluoxetine competes with cortisol for binding to human serum albumin. *Iran J Pharm Res* 2012;11:325-30.
26. Tsutsumi T, Ido A, Nakao K, Hamasaki K, Kato Y, Ohtsuru A, et al. Reciprocal regulation of α -fetoprotein and albumin gene expression by butyrate in human hepatoma cells. *Gastroenterology* 1994;107:499-504.
27. Prajapati KD, Sharma SS, Roy N. Upregulation of albumin expression in focal ischemic rat brain. *Brain Res* 2010;1327:118-24.
28. Meijerink J, Mandigers C, Van De Loch L, Tönnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. *J Mol Diagn* 2001;3:55-61.
29. Balaii H, Asadzadeh Aghdaei H, Farnood A, Habibi M, Mafi AA, et al. Time trend analysis and demographic features of inflammatory bowel disease in Tehran. *Gastroenterol Hepatol Bed Bench* 2015;8:253-61.
30. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, et al. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. *Proc Natl Acad Sci U S A* 2010;107:2598-603.
31. Taremi M, Mehdi Soltan Dallal M, Gachkar L, MoezArdalan S, Zolfagharian K, Reza Zali M. Prevalence and antimicrobial resistance of *Campylobacter* isolated from retail raw chicken and beef meat, Tehran, Iran. *Int J Food Microbiol* 2006;108:401-403.
32. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. *Biochim Biophys Acta* 2002;1602:114-30.
33. Fondevila C, Metges J, Fuster J, Grau J, Palacin A, Castells A, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. *Br J Cancer* 2004;90:206-15.
34. Chng W, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, et al. Clinical significance of TP53 mutation in myeloma. *Leukemia* 2007;21:582-5.

35. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005;353:2462-76.
36. Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. *Am J Gastroenterol* 2009;104:2222-32.
37. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994;330:1841-5.
38. Furstoss O, Dorey K, Simon V, Barilà D, Superti-Furga G, Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. *EMBO J* 2002;21:514-24.
39. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 1997;275:1132-6.
40. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shyanova T, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. *Genes Dev* 2001;15:2203-8.
41. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B, et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. *Biol Psychiatry* 2005;58:446-50.

Archive of SID